P3 Health Partners Inc

Aktienanalyse zu P3 Health Partners Inc (PIII)

$4.010

+0.199 (+4.97%)Zum Schluss

Loading chart…
Hoch
4.100
Eröffnung
3.970
Volumengewichteter Durchschnittskurs
4.03
Volumen
7.11K
Marktkap.
91.20M
Tief
3.970
Umsatz
28.62K
EV/EBITDA, TTM
3.35

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states.

ir.p3hp.org

KI-Analyse of P3 Health Partners Inc (PIII)

Kaufen

P3 Health Partners Inc. appears to be a good buy right now due to its recent turnaround in profitability, reporting a net income of $15.7 million in Q2 2026, a significant recovery from a loss of $43.7 million the previous year. Additionally, the stock is currently priced at $4.01, which is significantly lower than its 52-week high of $16.89, suggesting potential for upside. The forward P/E ratio is at 0, indicating that the stock is undervalued based on future earnings expectations. However, the main risk lies in its current debt situation, with a debt-to-equity ratio of 94.64%, which could impact financial stability if not managed properly.

Bewertungskennzahlen

Das aktuelle erwartete KGV von P3 Health Partners Inc (PIII) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -3.14.

Erwartetes KGV

Fair bewertet
5J-Durchschnitt P/E
-3.14
Aktuelles P/E
0.00
Überbewertet
3.05
Unterbewertet
-9.34

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
-2.05
Aktuelles EV/EBITDA
3.35
Überbewertet
90.93
Unterbewertet
-95.03

Erwartetes KUV

Stark überbewertet
5J-Durchschnitt P/S
0.13
Aktuelles P/S
0.46
Überbewertet
0.24
Unterbewertet
0.02

Alphio-AI-Kursszenarien für PIII

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%PIII

$8.18

Szenariopreis

B

Basis

Basis · 50%PIII

$7.60

Szenariopreis

B

Bärisch

Bärisch · 25%PIII

$6.61

Szenariopreis

Event-Zeitleiste

2026-10-15 (ET)

06:30:00

Selling Stockholders Plan to Sell 15.64M Shares of Class A Common Stock

2026-10-12 (ET)

09:30:00

P3 Health Partners Appoints Dr. Michael Millie as Chief Clinical Officer

2026-08-10 (ET)

16:30:00

Sees FY26 Adjusted EBITDA of $80M-$110M

16:30:00

P3 Reports Q2 Revenue of $386.38M, Beating Expectations

2026-05-19 (ET)

10:00:00

P3 Health Partners Inc Trading Resumes

News

PIII FAQ – beantwortet von Alphio AI

P3 Health Partners Inc. is a patient-centered and physician-led population health management company. The Company supports primary care providers with value-based care coordination and administrative services that improve patient outcomes and lower costs. Through partnerships with these local providers, it creates an enhanced patient experience by navigating, coordinating, and integrating the patient’s care within the healthcare system. Its technology platform, P3 Technology/Health Hub, enables physicians, care teams, patients and their family members to engage in the care journey. P3 Technology/Health Hub integrates clinical and claims data from disparate data points each month from payors, outpatient and inpatient facilities and other ancillary care settings. It has a network of more than 3,100 affiliated primary care providers across the country. Its local teams of healthcare professionals manage the care of thousands of patients in 27 counties across five states. It operates in the Healthcare sector (SERVICES-HEALTH SERVICES industry).

P3 Health Partners Inc. appears to be a good buy right now due to its recent turnaround in profitability, reporting a net income of $15.7 million in Q2 2026, a significant recovery from a loss of $43.7 million the previous year. Additionally, the stock is currently priced at $4.01, which is significantly lower than its 52-week high of $16.89, suggesting potential for upside. The forward P/E ratio is at 0, indicating that the stock is undervalued based on future earnings expectations. However, the main risk lies in its current debt situation, with a debt-to-equity ratio of 94.64%, which could impact financial stability if not managed properly.

Community

Mehr ↗

Noch keine Beiträge

Registriere dich oder melde dich an, um mitzudiskutieren

Ähnliche Artikel

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln